(Total Views: 397)
Posted On: 01/24/2021 1:38:14 PM
Post# of 145881
I think this really needs to be investigated pronto. S/C patients need circulating LL stat. Days of delay for LL to peak in the bloodstream is days S/C patients don't have.
A switch from subcutaneous to intravenous could make a huge difference with a huge effect on p values.
IV introduction of LL could be like kicking in the afterburners. All data on IV experience in any trials needs to be shown to the FDA along with CD12 results.
We must get the go ahead for IV!
Read More: https://investorshangout.com/messages/view?id...z6kUY4Az00
A switch from subcutaneous to intravenous could make a huge difference with a huge effect on p values.
IV introduction of LL could be like kicking in the afterburners. All data on IV experience in any trials needs to be shown to the FDA along with CD12 results.
We must get the go ahead for IV!
Read More: https://investorshangout.com/messages/view?id...z6kUY4Az00
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)